Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New program aims to keep hospital patients on track for opioid and meth recovery

NCT ID NCT06027814

Disease control Sponsor: University of Washington Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 16, 2026 · Updated 2 times

Summary

This study tests a program called MIAPP that adds a patient navigator, smartphone check-ins, and small rewards to usual care for people who start buprenorphine for opioid use in the hospital and also use methamphetamine. The goal is to help them connect to outpatient treatment within 30 days and stay on medication for 90 days. The study involves 40 adults and compares the new program to standard care alone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

40 people

The number who actually took part.

Started

Jan 2024

Finished

Oct 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult greater than or equal to 18 years of age * Admitted to Harborview Medical Center (HMC) on any inpatient service * Initiated on buprenorphine for OUD while in the hospital or at the time of discharge and planning to continue outpatient * Used methamphetamine within the past 30 days (any route of administration or frequency) * Willing to be randomized to video-DOT * Willing and able to use a smartphone (study can provide) and work with patient navigator * Discharge setting does not preclude the use of video-DOT (i.e., nursing home, inpatient psychiatry, etc.) Exclusion Criteria: * Unable or unwilling to use smartphone (phones to be provided when needed) * Cognitive impairment (acute or chronic) resulting in inability to provide informed consent * Currently incarcerated and will discharge to jail or prison * Plans to discontinue buprenorphine in the near future (\<3 months) * Lives far away such that cannot keep study visit at 30 days post-discharge * Not English speaking * Behavioral risk per discretion of research staff

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Medication adherence are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Medication Adherence methamphetamine dependence opiate dependence polysubstance abuse, susceptibility to

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Medication adherence Methamphetamine-dependence Opioid-use disorder Polysubstance drug use (indiscriminate drug use)

Contacts and locations

Locations

  • Harborview Medical Center

    Seattle, Washington, 98104, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.